Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR003013)
Formula
SVG example
Reactant Erlotinib hydrochloride Product Erlotinib M16
Reactant Info Product Info
Metabolic Enzyme DME Info
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR003021 Erlotinib hydrochloride Erlotinib M11 Oxidation - Oxidation Erlotinib hydrochloride [1]
MR003005 Erlotinib hydrochloride Erlotinib M13 Oxidation - O-demethylation Erlotinib hydrochloride [1]
MR003018 Erlotinib hydrochloride Erlotinib M14 Oxidation - O-demethylation Erlotinib hydrochloride [1], [2]
MR003019 Erlotinib hydrochloride Erlotinib M17 Unclear Erlotinib hydrochloride [1]
MR003020 Erlotinib hydrochloride Erlotinib M18 Oxidation - O-demethylation Erlotinib hydrochloride [1]
MR003022 Erlotinib hydrochloride Erlotinib M6 Oxidation - O-demethylation Erlotinib hydrochloride [1]
Other MR(s) Related to The Product of This MR
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR003017 Erlotinib M16 Erlotinib M17 Conjugation - O-glucuronidation Erlotinib hydrochloride [1]
MR003015 Erlotinib M16 Erlotinib M3 Unclear Erlotinib hydrochloride [1]
MR003014 Erlotinib M16 Erlotinib M7 Conjugation - O-glucuronidation Erlotinib hydrochloride [1]
MR003016 Erlotinib M16 Erlotinib M9 Unclear Erlotinib hydrochloride [1]
References
1 Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
2 Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.